معرفی
Gregory A. Abel, MD, MPH, is a Professor of Medicine at Harvard Medical School and a Senior Physician at Dana-Farber Cancer Institute (DFCI), where he is a member of the Divisions of Hematologic Malignancies and Population Sciences. He directs the Older Adult Hematologic Malignancy (OHM) Program and the Clinical Ethics Service at DFCI, and co-chairs the Ethics Advisory Committee. His clinical and research work bridges oncology, geriatrics, bioethics, and health services research.
- MD and MPH, Columbia University (2000)
- Residency in Internal Medicine, Massachusetts General Hospital
- Fellowship in Hematology/Oncology, Dana-Farber/Partners CancerCare
Dr. Abel’s research focuses on improving outcomes for patients with hematologic malignancies, especially older adults. His work emphasizes health services research, patient-reported outcomes, geriatric assessment, and ethical issues in cancer care. He investigates disparities in clinical trial access, the impact of frailty, and the integration of digital health tools. His recent studies explore AI ethics, climate-conscious medicine, and equity in eligibility criteria. He leads a research lab applying population-level data to enhance patient-centered care across the cancer trajectory.
His recent publications reflect a strong trend toward equity, ethics, and innovation in oncology. Key themes include racial disparities in trial access, digital health for functional monitoring, ethical deployment of AI, and sustainability in cancer care. He frequently publishes in top-tier journals such as JAMA Oncology, Blood, The Lancet Haematology, and The New England Journal of Medicine.
- Co-Chair, DFCI Ethics Advisory Committee
- Director, Clinical Ethics Service, DFCI
- Director, Older Adult Hematologic Malignancy Program
- Senior Physician, Dana-Farber Cancer Institute
Dr. Abel is deeply involved in mentoring, grant-funded research, and national guideline development, including contributions to American Society of Hematology guidelines. His work is supported by institutional and federal funding, though specific grants are not listed. He collaborates across disciplines, including oncology, geriatrics, bioethics, and public health, to address complex challenges in blood cancer care.
He is affiliated with multiple research centers, including the Adult Leukemia Program and the Population Sciences Division at DFCI. His lab focuses on real-world data, patient-reported outcomes, and intervention development to improve care delivery and equity.
